Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antipsychotic medication
dibenzoxazepine derivative |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 1975 |
| gptkbp:ATCCode |
N05AA09
|
| gptkbp:brand |
Adasuve
Loxitane |
| gptkbp:CASNumber |
1977-10-2
|
| gptkbp:chemicalClass |
tricyclic compound
|
| gptkbp:contraindication |
coma
CNS depression hypersensitivity to loxapine |
| gptkbp:eliminationHalfLife |
4 to 8 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C18H18ClN3O
|
| https://www.w3.org/2000/01/rdf-schema#label |
loxapine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist |
| gptkbp:metabolism |
liver
amoxapine |
| gptkbp:molecularWeight |
327.81 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:proteinBinding |
96.6%
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1423
4017 3879 DB00408 |
| gptkbp:relatedTo |
gptkb:clozapine
amoxapine |
| gptkbp:riskFactor |
gptkb:orthostatic_hypotension
seizures QT prolongation neuroleptic malignant syndrome tardive dyskinesia |
| gptkbp:routeOfAdministration |
oral
inhalation |
| gptkbp:sideEffect |
constipation
weight gain sedation dry mouth extrapyramidal symptoms |
| gptkbp:synonym |
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]oxazepine
|
| gptkbp:UNII |
GFD2T28MUC
|
| gptkbp:usedFor |
schizophrenia
acute agitation |
| gptkbp:bfsParent |
gptkb:Amoxapine
|
| gptkbp:bfsLayer |
7
|